

WE TAKE THE LEAD.

The ALS Therapy Development Institute (ALS TDI) operates one of the largest preclinical pharmacology programs in all of neurodegeneration.

We will advance 25-30 early stage molecules through rigorous screening using the SOD1 mouse model.

We dig data.

We will enroll 200 more people in our Precision Medicine Program (PMP).

In collaboration with Google, we will continue to apply artificial intelligence technology to our unique PMP data to better understand ALS.

We will work with the Broad Institute to expand our knowledge of ALS genetics.

We explore the possibilities.

We will characterize new models of ALS with the goal of using them to discover treatments.

We appreciate good company.

We will build on collaborations with Google and the Broad Institute, while continuing to work as world experts in ALS preclinical research with other organizations to validate potential treatments in our labs.

We aim to go deeper.

We will expand the scale of our small molecule drug discovery efforts using a combination of rational drug design and chemical library screens in neural cells derived from induced pluripotent stem cells (iPSCs).

We will enhance our longitudinal blood-based biomarker discovery program to identify biomarkers of disease progression.

We will not stop.

Our team is dedicated to finding effective therapies for ALS. We won't give up until there is a treatment for **every** person living with ALS.

Learn more at www.als.net.